This site is intended for healthcare professionals

Immunomedics announces phase III ASCENT study of sacituzumab govitecan to treat metastatic triple-negative breast cancer to be stopped for compelling efficacy.

Read time: 1 mins
Last updated:28th Jun 2021
Published:12th Apr 2020
Condition: Breast Cancer Triple Neg
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest